Compare Stocks → The Gold Grab of the Century (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTXNASDAQ:ATOSNASDAQ:CTICNASDAQ:IMVNASDAQ:ITRM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTXAptinyx$0.10+3.1%$0.08$0.01▼$0.72N/A1.271.32 million shs231,100 shsATOSAtossa Therapeutics$1.66+9.2%$1.50$0.62▼$2.31$208.00M1.272.26 million shs1.36 million shsCTICCTI BioPharma$9.09$9.06$4.01▼$9.10$1.20B0.834.50 million shsN/AIMVIMV$0.66$0.48▼$12.70$9.63M0.95233,607 shs44,800 shsITRMIterum Therapeutics$1.55-1.9%$1.53$0.62▼$2.50$25.67M2.33142,157 shs46,917 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTXAptinyx0.00%0.00%0.00%0.00%-20.00%ATOSAtossa Therapeutics0.00%+8.50%-20.95%+94.61%+150.60%CTICCTI BioPharma0.00%0.00%0.00%0.00%+75.82%IMVIMV0.00%0.00%0.00%0.00%0.00%ITRMIterum Therapeutics0.00%-7.19%-17.11%-1.27%+37.17%Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/AATOSAtossa Therapeutics1.1848 of 5 stars3.51.00.00.02.21.70.0CTICCTI BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics1.1567 of 5 stars3.53.00.00.00.60.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTXAptinyxN/AN/AN/AN/AATOSAtossa Therapeutics3.00Buy$4.50171.08% UpsideCTICCTI BioPharma2.00HoldN/AN/AIMVIMVN/AN/AN/AN/AITRMIterum Therapeutics3.00Buy$6.00287.10% UpsideCurrent Analyst RatingsLatest APTX, IMV, ATOS, CTIC, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.004/16/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/2/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/12/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$4.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.00(Data available from 5/5/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/AATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/ACTICCTI BioPharma$53M22.62N/AN/A($0.14) per share-64.93IMVIMV$330K0.00N/AN/A($0.69) per share0.00ITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/AATOSAtossa Therapeutics-$30.09M-$0.24N/AN/AN/AN/A-31.01%-29.77%5/20/2024 (Estimated)CTICCTI BioPharma-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/AIMVIMV-$37.99M-$4.59N/AN/AN/A-11,547.42%-12,695.41%-104.84%N/AITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)Latest APTX, IMV, ATOS, CTIC, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023ATOSAtossa TherapeuticsN/A-$0.06-$0.06-$0.06N/AN/A3/28/2024Q4 2023ITRMIterum Therapeutics-$1.02-$0.94+$0.08-$0.94N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTXAptinyxN/AN/AN/AN/AN/AATOSAtossa TherapeuticsN/AN/AN/AN/AN/ACTICCTI BioPharmaN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTXAptinyxN/AN/AN/AATOSAtossa TherapeuticsN/A17.6117.61CTICCTI BioPharmaN/A1.271.26IMVIMVN/A2.932.93ITRMIterum Therapeutics3.631.891.89OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTXAptinyxN/AATOSAtossa Therapeutics12.74%CTICCTI BioPharma91.45%IMVIMV15.37%ITRMIterum Therapeutics9.21%Insider OwnershipCompanyInsider OwnershipAPTXAptinyx10.97%ATOSAtossa Therapeutics7.80%CTICCTI BioPharma7.61%IMVIMV0.33%ITRMIterum Therapeutics5.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTXAptinyx12N/AN/ANot OptionableATOSAtossa Therapeutics12125.30 million115.53 millionOptionableCTICCTI BioPharma127131.88 million121.84 millionOptionableIMVIMV9711.71 million11.67 millionOptionableITRMIterum Therapeutics1416.56 million15.66 millionNot OptionableAPTX, IMV, ATOS, CTIC, and ITRM HeadlinesSourceHeadlineIterum Therapeutics (NASDAQ:ITRM) Given "Buy" Rating at HC Wainwrightamericanbankingnews.com - May 1 at 3:26 AMIterum Therapeutics PLC: Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenemfinanznachrichten.de - April 29 at 1:03 PMIterum Therapeutics resubmits new drug application to U.S. FDA for oral sulopenemmsn.com - April 29 at 1:03 PMIterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenemglobenewswire.com - April 29 at 8:00 AMIterum Therapeutics (NASDAQ:ITRM) vs. RedHill Biopharma (NASDAQ:RDHL) Head to Head Contrastamericanbankingnews.com - April 25 at 1:39 AMIterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 2 at 10:27 AMIterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 30 at 6:45 PMQ4 2023 Iterum Therapeutics PLC Earnings Callfinance.yahoo.com - March 29 at 2:40 AMIterum Therapeutics PLC: Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsfinanznachrichten.de - March 28 at 11:34 AMIterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 28 at 7:00 AMIterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024globenewswire.com - March 21 at 4:30 PMIterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chatglobenewswire.com - March 15 at 8:00 AMEQS-News: Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovationsmarkets.businessinsider.com - March 12 at 10:42 AMIterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Upzacks.com - March 7 at 9:00 AMIterum Therapeutics Provides Business Updatefinance.yahoo.com - March 6 at 7:38 PMIterum Therapeutics PLC (ITRM)investing.com - February 28 at 7:36 AMIterum Therapeutics (ITRM) Price Target Increased by 550.00% to 6.63msn.com - February 24 at 2:19 AMSteven Cohen's Point72 Asset Management Acquires New Stake in Iterum Therapeutics PLCfinance.yahoo.com - February 1 at 4:09 PMIterum Shareholders Reject Board’s Share Issuance Proposalmsn.com - February 1 at 12:05 AMIterum Therapeutics Announces Triumph in Phase 3 uUTI Trialmsn.com - January 31 at 7:49 AMWhy Iterum Therapeutics Stock Is Trending Todaymsn.com - January 30 at 4:48 PMIterum meets main goal in late trial for uUTI treatment with oral sulopenemmsn.com - January 30 at 4:48 PMIterum Therapeutics's Late-stage REASSURE Trial Successfully Met Primary Endpointmarkets.businessinsider.com - January 30 at 4:48 PMIterum Therapeutics Says UTI Drug Trial Met Primary Endpointmarketwatch.com - January 30 at 9:45 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptinyxNASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Atossa TherapeuticsNASDAQ:ATOSAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.CTI BioPharmaNASDAQ:CTICCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.IMVNASDAQ:IMVIMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.